XBiotech Inc. — 2016 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone fourth-quarter report. XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies, led by Xilonix (MABp1), an anti-IL-1 alpha therapy.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $42.5 million | $31.3 million |
| General and administrative expense | $10.3 million | $6.2 million |
| Total operating expenses | $52.8 million | $37.5 million |
| Net loss | $52.8 million | $37.5 million |
| Net loss per share | $1.63 | $1.22 |
| Cash used in operating activities | $46.0 million | $33.3 million |
| Cash used in investing activities | $13.9 million | $10.4 million |
| Cash and cash equivalents at year-end | $34.3 million | $91.1 million |
| Working capital at year-end | $29.0 million | $86.8 million |
| Total assets / total liabilities | $67.1 million / $8.0 million | $109.4 million / $6.3 million |
| Shareholders’ equity | $59.1 million | $103.1 million |
Margins are not meaningful because the company reported no revenue. The balance sheet reports no debt borrowing; liabilities primarily comprise accounts payable and accrued expenses. The accumulated deficit was $183.4 million. No product revenue or profitability is forecast with a clear amount in the filing.
Material changes and developments
- Net loss increased 41% year over year, while R&D expense rose 36%, mainly reflecting expanded global clinical activity, manufacturing development and a larger workforce. G&A increased 66%, including higher share-based compensation and professional fees.
- Operating cash use rose to $46.0 million. Investing cash use included $9.2 million for construction of the new manufacturing facility. Cash fell by $56.7 million during 2016.
- The company completed construction of a roughly 40,000-square-foot Austin manufacturing facility, intended to increase production capacity about ten-fold. Commercial readiness remained subject to validation and regulatory acceptance.
- After year-end, XBiotech received approximately $1.0 million from February 2017 share sales and raised approximately $31.6 million gross in a March 2017 registered direct offering, increasing shares outstanding and providing additional liquidity.
Outlook, commentary and key risks
- European regulatory review: XBiotech submitted an EMA marketing application for Xilonix in March 2016. In December 2016, the EMA issued outstanding issues concerning clinical benefit-risk justification and pharmacokinetics, as well as manufacturing quality matters. The filing describes an extended response deadline of March 22, 2017 and a pharmacokinetic study intended to support the response. Approval, timing and commercial launch were uncertain.
- U.S. Phase III trial: Enrollment in the advanced colorectal cancer study was completed in late 2016. The company reported that the February 2017 interim review found no safety concerns and supported continuing the trial without modification. This was not a final efficacy result; further interim and final overall-survival analyses remained pending.
- Other pipeline: A 20-patient hidradenitis suppurativa study reported a 60% response rate for MABp1 versus 10% for placebo (p=0.035) in February 2017. The company reported 514G3 enrollment completion for an S. aureus study; the timing and status of topline results are described inconsistently in the filing.
- Liquidity and funding: Management stated that year-end cash plus the March 2017 financing was expected to fund operations through one year from the report date and support several milestones. The company also warned that it expects continuing losses and may need substantial additional capital. Funding needs could result in dilution, debt obligations or partnership terms that limit company rights.
- Execution and commercialization: No products were approved or marketed. The company would need regulatory approvals, manufacturing validation, commercial infrastructure or a partner, payer reimbursement and market acceptance to generate sales. Clinical failure, delays, safety issues, competition and production scale-up could prevent commercialization.
- Legal contingency: A securities class action remained pending in California, with a tentative hearing date of April 14, 2017. The Texas action had been dismissed with prejudice. The company said it could not estimate the California case’s outcome or financial impact.
- The company reported effective disclosure controls and effective internal control over financial reporting based on management’s assessment. The independent auditor expressed an unqualified opinion on the financial statements but did not audit internal control effectiveness.
Most important facts for investors to verify
- Subsequent EMA decisions, resolution of clinical and manufacturing objections, and whether the new facility was validated for commercial production.
- Final overall-survival results from the U.S. Phase III colorectal cancer trial; the interim review was not conclusive proof of efficacy.
- Actual cash burn and runway after the March 2017 financing, including any later capital raises and resulting dilution.
- Progress and results for 514G3 and other pipeline programs, noting the filing’s inconsistent description of the 514G3 study status.
- Outcome and potential costs of the California securities litigation, and the cost and feasibility of commercialization and reimbursement.